Delivery Order SPE2DB20D2014-SPE2DB25FC54D
- Not listed
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $66,460.68 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and carries an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this delivery order, with performance taking place at the company's Conshohocken...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,340.32 on September 9, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $42,781.20 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on September 11, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, utilizing open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $12,141.94 by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $34,670.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract leveraging AmerisourceBergen's established pharmaceutical distribution capabilities. The contract is executed under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $43,038.15 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 mL pens with an ultimate completion date of August 11, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40,911 to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 25, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC54DDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $34,160.35 delivery order on July 23, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL vials). This non-competitive, firm fixed-price delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen maintains an extensive portfolio of pharmaceutical and medical supply deliveries primarily to military and veteran healthcare systems through the Defense Logistics Agency. This delivery order represents a routine transaction within AmerisourceBergen's comprehensive pharmaceutical prime vendor relationship with DLA, which enables the company to supply brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The company's federal contracting history demonstrates consistent capability in fulfilling competitive procurement requirements across diverse therapeutic domains and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.2k | 7/23/25 |